Drawing for Serial No. 88373373

USPTO serial 88373373

Serial No. 88373373

Reviewed by CopyMark Law Group

Reg. 6240448Status 702Renewal
Filing date
Status date
Registration date
Jan 5, 2021
Examiner
MORRIS, KRISTINA KLOIBER
Law office
Historical data usage

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with Serial No. 88373373?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $548*

Plus Government fees of $650

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark Leonardo

Mark Leonardo NUTTER, MCCLENNEN & FISH, LLP155 SEAPORT BOULEVARDSEAPORT WESTBOSTON, MA 02210

Goods and services

ClassDescriptionStatusFirst use
042Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposesACTIVEFeb 21, 2019
044Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slidesACTIVEFeb 21, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 4, 2026NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED—
Sep 4, 2026C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.—
Sep 4, 2026APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Jun 17, 2026TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 17, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 17, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 10, 2026E815TEAS SECTION 8 & 15 RECEIVED—
Jan 5, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jan 29, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 29, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 29, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 29, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 29, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jan 5, 2021R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 4, 2020SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 3, 2020CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Nov 24, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 24, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 17, 2020ALIEASSIGNED TO LIE—
Oct 13, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 13, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 13, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 13, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 11, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 2020CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 17, 2020SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Aug 12, 2020AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jul 31, 2020IUAFUSE AMENDMENT FILED—
Jul 31, 2020EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jul 8, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jul 8, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 8, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 8, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 8, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 5, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 3, 2020EX1GSOU EXTENSION 1 GRANTED—
Mar 3, 2020EXT1SOU EXTENSION 1 FILED—
Mar 3, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 3, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 14, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 14, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 9, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 9, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 19, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 30, 2019ALIEASSIGNED TO LIE—
May 15, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 15, 2019XAECEXAMINER'S AMENDMENT ENTERED—
May 15, 2019GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
May 15, 2019GNEAEXAMINERS AMENDMENT E-MAILED—
May 15, 2019CNEAEXAMINERS AMENDMENT -WRITTEN—
May 8, 2019GPRNNOTIFICATION OF PRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 8, 2019GPRAPRIORITY ACTION E-MAILEDA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 8, 2019CPRAPRIORITY ACTION WRITTENA priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline.
May 1, 2019DOCKASSIGNED TO EXAMINER—
Apr 25, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Apr 23, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 9, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance